deCODE and UCB Announce Discovery and Development Collaboration for Anti-Inflammatory Drugs
News Feb 09, 2009
deCODE chemistry & biostructures has announced the initiation of a collaboration with UCB. Under the terms of the deal, deCODE and UCB will collaborate on the structure-based discovery of small molecule modulators of undisclosed cytokine targets.
The program will focus on integrated structure-based drug design leveraging deCODE’s Fragments of Life™ technology for lead identification and optimization. As the program advances, it may also capitalize on deCODE's expertise in ADMET and PK/PD. The financial terms of the research fee, milestone and royalty-bearing relationship were not disclosed.
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
How do Poison Frogs Protect Themselves Against Their Own Neurotoxin?News
Scientists are a step closer to resolving a related head-scratcher, how do these frogs keep from poisoning themselves?READ MORE
Methane Hydrate Formation Studied Using Novel MicroreactorNews
Researchers at the NYU Tandon School of Engineering are using a novel means of studying how methane and water form methane hydrate that allows them to examine discrete steps in the process faster and more efficiently.READ MORE